ANG Lifesciences India's Q4 FY 2025-26 Quarterly Results

Result Summary

• ANG Lifesciences India Ltd reported a 25.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 35.5%.
• Its expenses for the quarter were down by 0.3% QoQ and up 16.0% YoY.
• The net profit decreased 70.9% QoQ and decreased 33.0% YoY.
• The earnings per share (EPS) of ANG Lifesciences India Ltd declined at 1.07 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ANG Lifesciences India Ltd is a company engaged in the pharmaceutical industry, specializing in the production and distribution of a variety of pharmaceutical products. The company is known for manufacturing a wide range of formulations in the form of tablets, capsules, dry syrups, liquids, ointments, and injections. It primarily caters to domestic markets but also has a growing presence in international markets. As of the last update, there have been no major developments publicly announced. The company’s operations are aligned with the industry's standards, focusing on quality and innovation to meet healthcare needs.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), ANG Lifesciences India Ltd reported a total income of ₹23.67 crores. This represents a substantial increase of 25.3% compared to the previous quarter (Q3FY26), where the total income was ₹18.89 crores. Additionally, a year-over-year (YoY) comparison with Q4FY25, which had a total income of ₹17.47 crores, shows an increase of 35.5%. These figures illustrate a significant rise in revenue over both time frames. This section strictly adheres to the provided financial data metrics without extrapolating beyond the given figures.

Profitability

For Q4FY26, ANG Lifesciences India Ltd reported a loss before tax of ₹1.10 crores, which shows an improvement from the loss of ₹5.96 crores in Q3FY26, indicating a decrease of 81.5% in the loss margin. Compared to Q4FY25, where the loss was ₹3.89 crores, there is a 71.7% reduction in the loss before tax. The profit after tax for Q4FY26 was a negative ₹1.38 crores, compared to a negative ₹4.75 crores in Q3FY26 and a negative ₹2.06 crores in Q4FY25, reflecting a decrease in losses by 70.9% and 33.0% QoQ and YoY, respectively. Earnings per share also improved to -₹1.07 in Q4FY26 from -₹3.60 in Q3FY26 and -₹1.56 in Q4FY25.

Operating Metrics

Total expenses for the company in Q4FY26 amounted to ₹24.78 crores, which is slightly less than the ₹24.86 crores reported in Q3FY26, demonstrating a marginal decrease of 0.3%. When compared year-over-year to Q4FY25, with expenses at ₹21.36 crores, there is an increase of 16.0%. The tax expense for Q4FY26 was ₹0.28 crores, contrasting with a tax credit of -₹1.21 crores in Q3FY26 and -₹1.83 crores in Q4FY25, indicating a significant change in tax liabilities. The trends in these operating metrics are based solely on the figures provided, avoiding any derived interpretations or opinions.